版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
DiabetesMellitus
Diabetesmellitus(DM)isagroupofdiseasescharacterizedbyhighlevelsofbloodglucoseresultingfromdefectsininsulinproduction,insulinaction,orboth.Thetermdiabetesmellitusdescribesametabolicdisorderofmultipleaetiologycharacterizedbychronichyperglycaemiawithdisturbancesofcarbohydrate,fatandproteinmetabolismresultingfromdefectsininsulinsecretion,insulinaction,orboth.Theeffectsofdiabetesmellitusincludelong–termdamage,dysfunctionandfailureofvariousorgans.DefinitionDefinitionInsulindeficiencyInsulinresistanceHyperglycemiaCarbohydrateFatProteinLong-termdamagesinvariousorgansType1DiabetesMellitusType2DiabetesMellitusGestationalDiabetesMellitus(GDM)Othertypes:LADA(LatentAutoimmuneDiabetesinAdults)MODY(maturity-onsetdiabetesofyouth)SecondaryDiabetesMellitusTypesofDiabetes
Previouslycalledinsulin-dependentdiabetesmellitus(IDDM)orjuvenile-onsetdiabetes.Type1diabetesdevelopswhenthebody’simmunesystemdestroyspancreaticbetacells,theonlycellsinthebodythatmakethehormoneinsulinthatregulatesbloodglucose.Thisformofdiabetesusuallystrikeschildrenandyoungadults,althoughdiseaseonsetcanoccuratanyage.Type1diabetesmayaccountfor5%to10%ofalldiagnosedcasesofdiabetes.Riskfactorsfortype1diabetesmayincludeautoimmune,genetic,andenvironmentalfactors.Type1diabetesPreviouslycallednon-insulin-dependentdiabetesmellitus(NIDDM)oradult-onsetdiabetes.Type2diabetesmayaccountforabout90%to95%ofalldiagnosedcasesofdiabetes.Itusuallybeginsasinsulinresistance,adisorderinwhichthecellsdonotuseinsulinproperly.Astheneedforinsulinrises,thepancreasgraduallylosesitsabilitytoproduceinsulin.Type2diabetesisassociatedwitholderage,obesity,familyhistoryofdiabetes,historyofgestationaldiabetes,impairedglucosemetabolism,physicalinactivity,andrace/ethnicity.Type2diabetesisincreasinglybeingdiagnosedinchildrenandadolescents.Type2diabetesAformofglucoseintolerancethatisdiagnosedinsomewomenduringpregnancy.GestationaldiabetesoccursmorefrequentlyamongAfricanAmericans,Hispanic/LatinoAmericans,andAmericanIndians.Itisalsomorecommonamongobesewomenandwomenwithafamilyhistoryofdiabetes.Duringpregnancy,gestationaldiabetesrequirestreatmenttonormalizematernalbloodglucoselevelstoavoidcomplicationsintheinfant.Afterpregnancy,5%to10%ofwomenwithgestationaldiabetesarefoundtohavetype2diabetes.Womenwhohavehadgestationaldiabeteshavea20%to50%chanceofdevelopingdiabetesinthenext5-10years.GestationaldiabetesGDMGestationaldiabetesmellitus(GDM):anydegreeofglucoseintolerancewithonsetorfirstrecognitionduringpregnancy.MaygoawayafterthebabyisbornButsomewomenwiththistypeofdiabetesmaybemorelikelytodeveloppermanentdiabetesafterpregnancyCancauseproblemsforthebabyincludingheartandlungproblemsandproblemswiththebaby’ssugarOtherspecifictypesofdiabetesresultfromspecificgeneticconditions(suchasmaturity-onsetdiabetesofyouth),surgery,drugs,malnutrition,infections,andotherillnesses.Suchtypesofdiabetesmayaccountfor1%to5%ofalldiagnosedcasesofdiabetes.OthertypesofDMLatentAutoimmuneDiabetesinAdults(LADA)isaformofautoimmune(type
1diabetes)whichisdiagnosedinindividualswhoareolderthantheusualageofonsetoftype1diabetes.Alternatetermsthathavebeenusedfor"LADA"includeLate-onsetAutoimmuneDiabetesofAdulthood,"SlowOnsetType1"diabetes,andsometimesalso"Type1.5diabetes”.Often,patientswithLADAaremistakenlythoughttohavetype
2diabetes,basedontheirageatthetimeofdiagnosis.LADALADAMODY–MaturityOnsetDiabetesoftheYoungMODYisamonogenicformofdiabeteswithanautosomaldominantmodeofinheritance:Mutationsinanyoneofseveraltranscriptionfactorsorintheenzymeglucokinaseleadtoinsufficientinsulinreleasefrompancreaticß-cells,causingMODY.DifferentsubtypesofMODYareidentifiedbasedonthemutatedgene.MODYMODYMutationMODY1HNF-4aMODY2GlucokinaseMODY3HNF-1aMODY4IPF-1MODY5HNF-1bMODY6NeuroD1MODYGlucokinaseMODYrequiresnotreatment,whiletranscriptionfactorMODY(i.e.Hepatocytenuclearfactor-1alpha)requireslow-dosesulfonylureatherapy.Acromegaly,--GHCushingsyndrome,--CortisolThyrotoxicosis,--T3T4Pheochromocytoma,PHA--CA,catecholamineCancer,--lungcancer
ACTHChronicpancreatitis,--insulininsufficiencyDruginducedhyperglycemia:Beta-blockers-Inhibitinsulinsecretion.Corticosteroids-Causeperipheralinsulinresistanceandgluconeogensis.SecondaryDMHormoneswhichcanincreaseglucoseClinicalPresentationType1DMPolyuriaPolydipsiaPolyphagiaWeightlossWeaknessDryskinKetoacidosisType2DMPatientscanbeasymptomaticPolyuriaPolydipsiaPolyphagiaFatigueWeightlossMostpatientsarediscoveredwhileperformingurineglucosescreeningDiagnosisofDiabetesMellitusLaboratoryTests1.GlucosuriaTodetectglucoseinurine2.KetonuriaTodetectketonbodiesinurine3.FastingbloodglucoseGlucosebloodconcentrationinsamplesobtainedafteratleast8hoursofthelastmeal4.RandomBloodglucoseGlucosebloodconcentrationinsamplesobtainedatanytimeregardlessthetimeofthelastmealLaboratoryTests5.Glucosetolerancetest75gmofglucosearegiventothepatientwith300mlofwaterafteranovernightfastBloodsamplesaredrawn1,2,and3hoursaftertakingtheglucoseThisisamoreaccuratetestforglucoseutilizationifthefastingglucoseisborderline
Plusinsulinreleasetest(IRT)andC-peptidetestbetacellreserveevaluation5.Glucosetolerancetest(cont.)Itisestimatedmorethan50%ofbetacellswerelostattheonsetofdiabetes.LaboratoryTestsDisulfidebondValuesofDiagnosisofDiabetesMellitusValuesofDiagnosisofDiabetesMellitus75gmofglucosearegiventothepatientwith300mlofwaterafteranovernightfast(12h)----24-28wTimeGlucose(mmol/L)0h5.11h10.02h8.5Onetime-pointexceedsnormalrangeGDMGDMGLUCOSETEST6.Glycosylatedhemoglobin(HbA1C)HbA1CisformedbycondensationofglucosewithfreeaminogroupsoftheglobincomponentofhemoglobinNormallyitcomprises4-6%ofthetotalhemoglobin.Increaseintheglucosebloodconcentrationincreasestheglycatedhemoglobinfraction.HbA1Creflectstheglycemicstateduringthepreceding8-12weeks.LaboratoryTests7.SerumFructosamineFormedbyglycosylationofserumprotein(mainlyalbumin)Sinceserumalbuminhasshorterhalflifethanhemoglobin,serumfructosaminereflectstheglycemicstateinthepreceding2weeksNormalis1.5-2.4mmol/Lwhenserumalbuminis5g/dL.LaboratoryTestsLaboratoryTests8.AutoantibodiesInsulinautoantibody(IAA):morefrequentlydetectedinveryyoungchilddiabetesIsletcellantibody(ICA):morefrequentlydetectedinjuvenilediabetesGlutamicaciddecarboxylase(GADA):appearsrelativelylatePrediabetesisatermusedtodistinguishpeoplewhoareatincreasedriskofdevelopingdiabetes.Peoplewithprediabeteshaveimpairedfastingglucose(IFG)orimpairedglucosetolerance(IGT).SomepeoplemayhavebothIFGandIGT.IFGisaconditioninwhichthefastingbloodsugarleveliselevated(6.1-6.9mmol/L)afteranovernightfastbutisnothighenoughtobeclassifiedasdiabetes.IGTisaconditioninwhichthebloodsugarleveliselevated(7.8-11.1mmol/L)aftera2-houroralglucosetolerancetest,butisnothighenoughtobeclassifiedasdiabetes.Prediabetes:Impairedglucosetoleranceandimpairedfastingglucose
DiagnosticCriteria
CharacteristicsType1Type2%ofdiabeticpop5-10%90%AgeofonsetUsually<30yr+someadultsUsually>40+someobesechildrenPancreaticfunctionUsuallynoneInsulinislow,normalorhighPathogenesisAutoimmuneprocessAuto-antibodiespositive(GADA+)Defectininsulinsecretion,tissueresistancetoinsulinAuto-antibodiesnegativeFamilyhistoryGenerallynotstrongStrongObesityUncommonCommonHistoryofketoacidosisOftenpresentRareexceptinstressClinicalpresentationmoderatetoseveresymptoms:3Ps,fatigue,wtlossandketoacidosisMildsymptoms:Polyuriaandfatigue.DiagnosedonroutinephysicalexaminationTreatmentInsulin,DietExerciseDiet,ExerciseOralantidiabetics,InsulinManagementofDiabetesMellitusThemajorcomponentsofthetreatmentofdiabetesare:ManagementofDMADiet,Exercise,andSelfcareBOralhypoglycaemictherapyCInsulinTherapy
GlycemicgoalsDietisabasicpartofmanagementineverycase.Treatmentcannotbeeffectiveunlessadequateattentionisgiventoensuringappropriatenutrition.Dietarytreatmentshouldaimat:ensuringweightcontrolprovidingnutritionalrequirementsallowinggoodglycaemiccontrolwithbloodglucoselevelsasclosetonormalaspossiblecorrectinganyassociatedbloodlipidabnormalitiesA.1DietThefollowingprinciplesarerecommendedasdietaryguidelinesforpeoplewithdiabetes:Dietaryfatshouldprovide25-35%oftotalintakeofcaloriesbutsaturatedfatintakeshouldnotexceed10%oftotalenergy.Cholesterolconsumptionshouldberestrictedandlimitedto300mgorlessdaily.Proteinintakecanrangebetween10-15%totalenergy(0.8-1g/kgofdesirablebodyweight).Requirementsincreaseforchildrenandduringpregnancy.Proteinshouldbederivedfrombothanimalandvegetablesources.Carbohydratesprovide50-60%oftotalcaloriccontentofthediet.Carbohydratesshouldbecomplexandhighinfibre.Excessivesaltintakeistobeavoided.Itshouldbeparticularlyrestrictedinpeoplewithhypertensionandthosewithnephropathy.A.1Diet(cont.)Physicalactivitypromotesweightreductionandimprovesinsulinsensitivity,thusloweringbloodglucoselevels.Togetherwithdietarytreatment,aprogrammeofregularphysicalactivityandexerciseshouldbeconsideredforeachperson.Suchaprogrammemustbetailoredtotheindividual’shealthstatusandfitness.Peopleshould,however,beeducatedaboutthepotentialriskofhypoglycaemiaandhowtoavoidit.A.2ExercisePatientsshouldbeeducatedtopracticeself-care.Thisallowsthepatienttoassumeresponsibilityandcontrolofhis/herowndiabetesmanagement.Self-careshouldinclude:BloodglucosemonitoringBodyweightmonitoringFoot-carePersonalhygieneHealthylifestyle/dietorphysicalactivityIdentifytargetsforcontrolStoppingsmokingA.3Self-Care
Therearecurrentlysixclassesoforalanti-diabeticagents:i.Biguanidesii.InsulinSecretagogues–SulphonylureasandGlinidesiii.α-glucosidaseinhibitorsiv.Thiazolidinediones(TZDs)v.DPP4(dipeptidylpeptidase4)inhibitorsvi.SGLT(sodium-glucosecotransporter-2)inhibitorsB.OralAnti-DiabeticDrugs(OADs)OralHypoglycaemicMedicationsMajorTherapeuticTargetsinT2DMGlucose
absorptionHepaticglucose
overproductionInsulin
resistancePancreasMuscleandfatLiverMetforminThiazolidinedionesGLP-1agonistsDPP-4inhibitorsSulfonylureasMeglitinidesGLP-1agonistsDPP-4inhibitorsThiazolidinedionesMetforminAlpha-glucosidaseinhibitorsGLP-1agonistsGutGlucose
reabsorptionKidneyBeta-cell
dysfunctionGlucoselevelSGLT-2inhibitorsAbbreviations:DPP-4,dipeptidylpeptidase-4;GLP-1,glucagon-likepeptide-1;T2DM,type2diabetesmellitus.41B1.SulfonylureasPharmacologicaleffectStimulatethepancreaticsecretionofinsulinSulfonylureasbindtoandclose
ATP-sensitiveK+(KATP)channelsonthecellmembraneofpancreatic
betacells,whichdepolarizesthecellbypreventingpotassiumfromexiting.This
depolarization
opensvoltage-gated
Ca2+
channels.Theriseinintracellularcalciumleadstoincreasedfusionof
insulin
granulaewiththecellmembrane,andthereforeincreasedsecretionof(pro)insulin.43B1.Sulfonylureas(Cont’d)ClassificationFirstgeneratione.g.tolbutamide,chlorpropamide,andacetohexamideLowerpotency,morepotentialfordruginteractionsandsideeffectsSecond/Thirdgeneratione.g.glimepiride,glipizide,andglyburidehigherpotency,lesspotentialfordruginteractionsandsideeffectsAllsulfonylureadrugsareequallyeffectiveinreducingthebloodglucosewhengiveninequipotentdoses.MajorPharmacokineticPropertiesofSulfonylureasEqv.Dose(mg)Duration(h)ActivemetabolitesFirstGenerationTolbutamide1000-150012-24Yes(p-OHderivative)Chlorpropamide250-37524-60Yes(2’-OHand3’OHgroups)Tolazamide250-37512-24No(4-COOHderivative)Secondgeneration
Glipizide1010-24No(cleavageofpyrazinering)
Glyburide(glibenclamide)
Thirdgeneration516-24Some(trans+cis4’-OHgroups)
Glimepiride1-224Yes(-OHonCH3ofR’group)B1.Sulfonylureas(Cont’d)AdverseeffectsHypoglycemiaWeightgainHbA1c:1.5–1.7%reduction.FPG:50–70mg/dLreduction.PPG:92mg/dLreduction.EfficacyB2.GlinidesPharmacologicaleffectStimulationofthepancreaticsecretionofinsulinShouldbegivenbeforemealorwiththefirstbiteofeachmeal.Ifyouskipamealdon’ttakethedose!RepaglinideNateglinideShort-actingSecretogoguesTheybindtoan
ATP-dependent
K+
(KATP)channelonthecellmembraneofpancreatic
betacells
inasimilarmannerto
sulfonylureas
buthaveaweakerbindingaffinityandfasterdissociationfromtheSUR1bindingsite.Glinides48Incidenceofhypoglycemiaisverylowabout0.3%AdverseeffectDrugInteractionsInducersorinhibitorsofCYP3A4affecttheactionofrepaglinideNateglinideisaninhibitorofCYP2C9B2.GlinidesB3.BiguanidesPharmacologicaleffectReduceshepaticglucoseproductionIncreasesperipheralglucoseutilizationMetforminAdverseeffectsNausea,vomiting,diarrhea,andanorexiaAsaprecautionmetforminshouldnotbeusedinpatientswithrenalinsufficiency,CHF,conditionsthatleadtohypoxiaB4.Glitazones(PPARgAgonists)PPARgAgonists:Peroxisomeproliferator-activatedreceptorggonistsRosiglitazone-PioglitazoneReducesinsulinresistanceintheperiphery(Sensitizemuscleandfattotheactionofinsulin)andpossiblyintheliverTheonsetofactionisslowtaking2-3monthstoseethefulleffectEdemaandweightgainarethemostcommonsideeffects.(nohepatotoxicity)PharmacologicaleffectPPARrAgonistB5.a-GlucosidaseInhibitorsPharmacologicaleffectPreventthebreakdownofsucroseandcomplexcarbohydratesTheneteffectistoreducepostprandialbloodglucoseriseTheeffectislimitedtotheluminalsideoftheintestinewithlimitedsystemicabsorption.Majorityeliminatedinthefeces.Postprandialglucoseconcisreduced.FPGrelativelyunchanged.AveragereductioninHbA1c:0.3-1.0%-Acarbose-Voglibose-MiglitolAtinsulininitiation,theaveragepatienthad:5yearswithHbA1c>8%10yearswithHbA1c>7%TraditionalApproachestoTherapyResult
inProlongedExposuretoElevatedGlucoseBrownJB,etal.DiabetesCare.2004;27(7):1535-1540.SulfonylureaorMetforminMonotherapyCombination
TherapyDiet/ExerciseMeanHbA1cat
LastVisit(%)Years Diagnosis 2 3 4 5 6 7 8 9 108.6%678910Insulin9.6%ADAGoal<7%AACEGoal<6.5%9.0%Inelderlynon-obesepatients,shortactinginsulinsecretagoguescanbestartedbutlongactingSulphonylureasaretobeavoided.Renalfunctionshouldbemonitored.Oralanti-diabeticagentsarenotrecommendedfordiabetesinpregnancyOralanti-diabeticagentsareusuallynotthefirstlinetherapyindiabetesdiagnosedduringstress,suchasinfections.InsulintherapyisrecommendedforboththeaboveTargetsforcontrolareapplicableforallagegroups.However,inpatientswithco-morbidities,targetsareindividualizedWhenindicated,startwithaminimaldoseoforalanti-diabeticagent,whilereemphasizingdietandphysicalactivity.Anappropriatedurationoftime(2-16weeksdependingonagentsused)betweenincrementsshouldbegiventoallowachievementofsteadystatebloodglucosecontrolGeneralGuidelinesforUseofOralAnti-DiabeticAgentinDiabetes
Asfirstlinetherapy:Obesetype2patients,consideruseofmetformin,acarboseorTZD.Non-obesetype2patients,considertheuseofmetforminorinsulinsecretagoguesMetforministhedrugofchoiceinoverweight/obesepatients.TZDsandacarboseareacceptablealternativesinthosewhoareintoleranttometformin.Ifmonotherapyfails,acombinationofTZDs,acarboseandmetforminisrecommended.Iftargetsarestillnotachieved,insulinsecretagoguesmaybeaddedOralAgentMonotherapyCombinationoralagentsisindicatedin:NewlydiagnosedsymptomaticpatientswithHbA1c>7.5Patientswhoarenotreachingtargetsafter3monthsonmonotherapyCombinationOralAgents
C.InsulinTherapyThenumberofunits/ml e.g.U-100,U-20,U-10StrengthSourceSwine:Differsbyonea.a.OxHuman(recombinantDNAtechnology)C.InsulinTherapy-insulintype
C.Insulin(Cont’d)-insulintypeChangingthepropertiesofinsulinpreparationcanaltertheonsetanddurationofactionLispro:(Monomeric)absorbedtothecirculationveryrapidlyAspart: (Mono-anddimeric)absorbedtothecirculationveryrapidlyOnsetanddurationofeffectC.Insulin(Cont’d))-insulintypeLenteinsulin:Amorphousprecipitateofinsulinandzincandinsolublecrystalsofinsulinandzinc.ReleasesinsulinslowlytothecirculationNPH:R-insulin+Protaminezincinsulin.ReleasesinsulinslowlytothesystemiccirculationInsulinglargine:Preparedbymodificationoftheinsulinstructure.PrecipitateafterS.C.injectiontoformmicrocrystalsthatslowlyreleaseinsulintothesystemiccirculation(N.B.cannotbemixedwithotherinsulins)OnsetanddurationofeffectC.Insulin(Cont’d))-insulintypeRapid-actinginsuline.g.InsulinlisproandinsulinaspartShort-actinginsuline.g.Regularinsulin(RI),Novolin-R,Humulin-RIntermediate-actinginsuline.g.NPHandLenteinsulinLong-actinginsuline.g.InsulinGlargineMixtureofinsulincanprovideglycemiccontroloverextendedperiodoftimee.g.Novomix30(70%NPH+30%NovorapidAspart)OnsetanddurationofeffectC.Insulin(Cont’d)HypoglycemiaTreatment:
PatientsshouldbeawareofsymptomsofhypoglycemiaOraladministrationof10-15gmglucoseIVglucoseinpatientswithlostconsciousness1gmglucagonIMifIVaccessisnotavailableSkinrashatinjectionsiteTreatment:
UsemorepurifiedinsulinpreparationLipodystrophies(increaseinfatmass)atinjectionsiteTreatment:
rotatethesiteofinjectionAdverseeffectsC.Insulin(Cont’d)MethodsofInsulinAdministrationInsulinsyringesandneedlesPen-sizedinjectorsInsulinPumpsRINovoMix30NovoRapidShort-termuse:Acuteillness,surgery,stressandemergenciesPregnancyBreast-feedinginmarkedhyperglycaemiaSeveremetabolicdecompensation(diabeticketoacidosis,hyperosmolarnonketoticcoma,lacticacidosis,severehypertriglyceridaemia)C.Insulin-Therapy-Howtouseinsulin
Long-termuse:IftargetshavenotbeenreachedafteroptimaldoseofOADcombinationtherapy,considerchangetoinsulintherapy.C.Insulin-Therapy-Howtouseinsulin
Howtouseinsulin:1Regimen2DoseNormalinsulinsecretionduringadayBreakfastLunchSupperInsulinConcentrationTimeofday-Constantbackgroundlevel(basal)-SpikesofinsulinsecretionaftereatingTheinsulinregimenhastomimicthephysiologicalsecretionofinsulinThemajorityofpatientswillrequiremorethanonedailyinjectionifgoodglycaemiccontrolistobeachieved.However,aonce-dailyinjectionofanintermediateactingpreparationmaybeeffectivelyusedinsomepatients.Twice-dailymixturesofshort-andintermediate-actinginsulinisacommonlyusedregimen.Third-dailymixturescanbechosewhentwice-injectionregimencannotgettheglucosetarget.Threeinjectionsofregularorrapidactinginsulinbeforeeachmeal+longactinginsulinatbedtime(4injections).Insomecases,amixtureofshort-andintermediate-actinginsulinmaybegiveninthemorning.Furtherdosesofshort-actinginsulinaregivenbeforelunchandtheeveningmealandaneveningdoseofintermediate-actinginsulinisgivenatbedtime.InsulinPumpThechoiceoftheregimenwilldependonthepatient
C.Insulin-Therapy--Insulinregimens
C.Insulin-Therapy--InsulinregimensBreakfastLunchSupperInsulinConcentrationGlarginecontrolbaseglucoselevelAcarbosecontrolmealtimeglucoselevelGlargineAcarboseAcarboseAcarboseCombinationofinsulin+oralanti-diabeticagentshasbeenshowntoimproveglycaemiccontrolinthosenotachievingtargetdespitemaximalcombinationoralanti-diabeticagents.Combininginsulinandthefollowingoralanti-diabeticagentshasbeenshowntobeeffectiveinpeoplewithtype2diabetes:Biguanide(metformin)Insulinsecretagogues(sulphonylureas)α-glucosidaseinhibitor(acarbose)InsulindosecanbeincreaseduntiltargetFPGisachieved.CombinationOralAgentsandInsulin
C.Insulin-Therapy--InsulinregimensBreakfastLunchSupperInsulinConcentrationNovoMix30+AcarboseNovoRapid(30%Aspart)controlbaseglucoselevelNovoLinNPH(ProtamineInsulinAspart70%)controlmealtimeglucoselevelNovoMix30NovoMix30NovoMix30AcarboseC.Insulin-Therapy--InsulinregimensBreakfastLunchSupperInsulinConcentrationGlarginecontrolbaseglucoselevelNovoRapidcontrolmealtimeglucoselevelNovoRapidGlargineNovoRapidNovoRapidC.Insulin-Therapy--InsulinregimensBreakfastLunchSupperInsulinConcentrationIusulinpumpBasecontrolbaseglucoselevelBoluscontrolmealtimeglucoselevelBolusBaseBolusBolusInsulinPumpTheinsulinpumpdeliversasingletypeofrapid-actinginsulinintwoways:abolusdosethatispumpedtocoverfoodeatenortocorrectahighbloodglucoselevel.abasaldosethatispumpedcontinuouslyatanadjustablebasalratetodeliverinsulinneededbetweenmealsandatnight.CSII:ContinuoussubcutaneousinsulininfusionHowmuchinsulin?1injection+OADAgoodstartingdoseis0.2-0.4U/kg/dayExample:Fora50kgpatientThetotaldose=0.2X50=10U/dayGlargine10uihbeforesleep
C.Insulin-Therapy--InsulindoseHowmuchinsulin?2injections3injectionsAgoodstartingdoseis0.4-0.6U/kg/dayThetotaldoseshouldbedividedto:
-3/6pre-breakfast -1/6pre-lunch -2/6pre-supper
C.Insulin-Therapy--Insulindose
-2/3pre-breakfast-1/3pre-supper
Example:Fora50kgpatientThetotaldose=0.6X50=30U/day2injections:20upre-breakfast(Novomix3020uih)10upre-supper(Novomix3010uih)3injections:15upre-breakfast(Novomix3015uih)5upre-lunch(Novomix3010uih)10upre-supper(Novomix3010uih)
C.Insulin-Therapy--InsulindoseHowmuchinsulin?4injections,5injections,insulinpumpAgoodstartingdoseis0.4-0.6U/kg/dayThetotaldoseshouldbedividedto:50%forbasalinsulin50%forprandialinsulinTheprandialdoseisdividedto
- 1/3pre-breakfast -1/3pre-lunch -1/3pre-supper
C.Insulin-Therapy--InsulindoseExample:Fora50kgpatientThetotaldose=0.6X50=30U/day15Uforbasalinsulin(50%ofdose)Administeredinone(Glargine)ortwodoses(NPH)orbaserate(insulinpump,0.6u/h)15Uforprandialinsulin(50%ofdose)The15Uaredividedto:
- 5Upre-breakfast(Aspart5uihorinsulinpumpbolus5u) -5Upre-lunch(Aspartorinsulinpumpbolus5u) -5Upre-supper(Aspartorinsulinpumpbolus5u)
C.Insulin-Therapy--InsulindoseLimitationsofAgentsforT2DMLimitationAgentHypoglycemiaSecretagogues,insulinWeightgainSecretagogues,glitazones,insulinEdemaGlitazones,insulinGIsideeffectsMetformin,alpha-glucosidaseinhibitorsLacticacidosis(rare)MetforminSafetyissuesinelderly,renal-impaired,orCHFpatientsGlitazones,metformin,sulfonylureasPoorresponseratesAlloralmedicationsLackofdurableeffectAlloralmonotherapyexceptglitazonesAbbreviations:CHF,congestiveheartfailure;GI,gastrointestinal.ComplicationsofdiabetesmellitusComplicationsofdiabetesmellitusAcutecomplications:KetoacidosisThehyperglycemichyperosmolarnonketoticsyndromeHypoglycemiaChroniccomplications:DisordersofthemicrocirculationNeuropathiesNephropathiesRetinopathiesMacrovascularcomplicationsFootulcersThelong–termeffectsofdiabetesmellitusincludeprogressivedevelopmentofthespecificcomplicationsofretinopathywithpotentialblindness,nephropathythatmayleadtorenalfailure,and/orneuropathywithriskoffootulcers,amputation,Charcotjoints,andfeaturesofautonomicdysfunction,includingsexualdysfunction.Peoplewithdiabetesareatincreasedriskofcardiovascular,peripheralvascularandcerebrovasculardisease.Chroniccomplications1.PeripheralneuropathiesTwotypesofpathologicchangeshavebeenobservedinconnectionwithdiabeticperipheralneuropathies.Thefirstisathickeningofthewallsofthenutrientvesselsthatsupplythenerve,leadingtotheassumptionthatvesselischemiaplaysamajorroleinthedevelopmentoftheseneuralchanges.ThesecondfindingisasegmentaldemyelinizationprocessthataffectstheSchwanncell.Thisdemyelinizationprocessisaccompaniedbyaslowingofnerveconduction.Theclinicalmanifestationsofthediabeticperipheralneuropathiesvarywiththelocationofthelesion.ClassificationofdiabeticperipheralneuropathiesSomatic:Polyneuropathies(bilateralsensory)Paresthesias,includingnumbnessandtinglingImpairedpain,temperature,lighttouch,two-pointdiscrimination,andvibratorysensationDecreasedankleandknee-jerkreflexesMononeuropathiesInvolvementofamixednervetrunkthatincludeslossofsensation,pain,andmotorweakness.AmyotrophyAssociatedwithmuscleweakness,wasting,andseverepainofmusclesinthepelvicgirdleandthigh.Autonomic:ImpairedvasomotorfunctionPosturalhypotensionImpairedgastrointestinalfunctionGastricatonyDiarrhea,
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 《学前儿童卫生与保育》 课件 项目七 学前儿童意外伤害的护理与急救
- 河海大学桩基变形特性小型模型试验系统设备招标预告(二次)
- 北师大版小学英语五年级下册模拟试卷含参考答案
- 2022-2023学年甘肃省陇南市高一下学期期末考试化学试题(解析版)
- 2024合同范本,馆舍租房合同
- 2023年双偏振天气雷达项目调研分析报告
- 第一单元任务二《新闻采访》公开课一等奖创新教学设计 统编版语文八年级上册
- 膜生物反应器滤池系统改进
- 2024年劳动合同法关于工作时间的规定
- 反应器设计优化乳酸发酵传质
- 暑假生活相册模板
- 2024~2024二年级班主任工作计划5篇
- 专题20 读后续写语料积累之如何表达愤怒背诵与测试(词-句-文)讲义高考英语读后续写高分宝典 解析版
- 2024至2030年中国鹅养殖业行业市场发展监测及投资潜力预测报告
- 2024年中国移动通信集团天津限公司校园招聘(高频重点提升专题训练)共500题附带答案详解
- 医院改善就医感受提升患者体验案例
- 老旧小区改造项目重点与难点分析
- DL∕T 802.4-2023 电力电缆导管技术条件 第4部分:波纹类塑料电缆导管
- 医院信息系统使用管理制度
- 2024年中考英语新热点时文阅读-中华文化(二)
- 完整版大学生宪法知识竞赛题库及答案完整版完整版
评论
0/150
提交评论